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Objectives The efficacy of left atrial appendage (LAA) occlusion using the Transcatheter Patch (TP) (Custom Medical De-
vices, Athens, Greece) in conjunction with surgical adhesives was assessed.
Background The TP is a bioabsorbable device that can be adjusted for the shape and size of the LAA without the risk of per-
foration. It is attached by a surgical adhesive and is released in 45 min.
Methods Occlusion of the LAA was performed in 20 high-risk patients, 59 to 89 years of age, with atrial fibrillation. A
2-stage polyethylene glycol surgical adhesive was applied to the distal half of the device. Activation of the adhe-
sive was achieved by direct injection of alkaline solution. Fluoroscopy and transesophageal echocardiography
only were used for device placement in 17 patients. In 3 patients, angiography was used as well. Follow-up
transesophageal echocardiography was performed upon discharge.
Results The procedure was successful in 17 cases. In the 3 patients in whom angiography was performed, the
patch did not attach and was retrieved. In 1 case, the patch was placed beyond the mouth of the append-
age, resulting in a residual opening. There was further improvement of the occlusion rate on the follow-up
transesophageal echocardiography. There was 1 complication related to the procedure, namely, thrombus
was released from the long sheath in the left atrium upon withdrawal and required treatment to be dis-
solved. No recurrent strokes were reported.
Conclusions Occlusion of the LAA by the TP is feasible and effective in most patients with atrial fibrillation at high risk
for embolic stroke. Angiography before placement probably affects patch adhesion and is contraindicated.
(J Am Coll Cardiol 2011;58:2236–40) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.036F
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oAtrial fibrillation is the most common cause of embolic
stroke in cases with nonvalvular disease (1). Transesopha-
geal echocardiography (TEE) has shown that the left atrial
appendage (LAA) is the most common site for thrombus
formation, and criteria have been defined for patients who
are at high risk for thrombosis (2). Warfarin treatment has
been the traditional method for stroke prophylaxis in
patients with atrial fibrillation; however, there are several
problems related to efficacy, side effects, and compliance
with treatment (3). Non-warfarin medications show prom-
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accepted August 2, 2011.ise, but they require long-term evaluation (4). Surgical and
thoracoscopic obliterations of the LAA have been used, but
they are associated with known surgical morbidity (5,6).
Metal devices have also been used successfully for the
occlusion of the LAA, but concerns remain regarding
thrombogenicity, risk for perforation, and embolization (7).
urthermore, because the size of the appendage varies,
everal device sizes are required for the same procedure (8).
AA obliteration by the Transcatheter Patch (TP) (Custom
edical Devices, Athens, Greece) could be an effective
lternative, as it potentially reduces the long-term risks of
erforation, thromboembolism, and embolization. Addi-
ionally, the patch is balloon deliverable and can conform to
ll or most LAAs, necessitating only a single size device.
Effectiveness and safety have been demonstrated in TP
bliteration of the LAA in piglets using accelerated fibrin
ormation principles and surgical adhesives (9). Use of
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November 15, 2011:2236–40 Transcatheter Patch LA Appendage Closuresurgical adhesives appeared very attractive in animal studies
as the patch could be released in as early as 15 min. The
purpose of this study was to assess the effectiveness of TP
obliteration of the LAA using the surgical adhesives method
in patients with atrial fibrillation at high risk with warfarin
treatment.
Methods
LAA occlusion was performed in 20 high-risk patients, 59
to 89 years of age, with idiopathic atrial fibrillation. In-
formed consent was obtained from each patient. All patients
had a CHADS2 score 3 (clinical prediction rule for
estimating the risk of stroke: C  congestive heart failure,
H  hypertension, A  age, D  diabetes, S2  prior
stroke or transient ischemic attack). Previous stroke existed
in 8, intolerance or contraindication to warfarin in 10,
bleeding ulcer in 9, congestive heart failure in 5, diabetes in
5, and old LAA thrombus in 3. There was also a single
patient who was recently converted to sinus rhythm by
ablation, but was unable to take warfarin. Further patient
information can be seen in Table 1.
Fluoroscopy and TEE were used throughout the proce-
dure. The atrial septum was perforated using standard
transseptal puncture techniques. A multipurpose catheter
was advanced in the LAA, and the position, size, and shape
of the appendage were confirmed by TEE in all patients and
by angiography in 3 patients. A 0.035-inch exchange wire
was positioned deeply in the appendage, and a 13-F long
Mullins sheath (Cook, Bloomington, Indiana) was ad-
vanced to the appendage over the guidewire.
Transcatheter patch. The TP, shown in Figure 1, is a
frameless, balloon-deliverable device used for the occlusion
Patient InformationTable 1 Patient Information
Patient # Age (Yrs) LAA (mm) TP (mm)
1 79 20 21
2 71 18 20
3 59 19 21
4 62 16 29
5 75 23 24
6 89 17 29
7 70 20 21
8 76 24 25
9 64 14 20
10 75 23 24
11 75 18 20
12 74 17 19
13 75 15 16
14 80 21 23
15 70 18 20
16 75 20 22
17 75 24 25
18 82 21 23
19 80 20 22
20 75 19 21con.  contraindicated; FO  full occlusion; LA  left atrium; LAA  left atrial appendage; PO  partialof heart defects. The patches are
tailored from polyurethane foam
(Foamex, Media, Pennsylvania).
The supporting balloon is made
from Latex (NuMED, Hopkin-
ton, New York) and is inflated to
diameters of 15 to 25 mm by
diluted contrast. A 2-mm nylon
loop is sutured at the bottom of
the patch, to which a double nylon thread is connected for
retrieval purposes.
Surgical adhesive. A pH-activated polyethylene glycol
based surgical adhesive is used (Baxter, Deerfield, Illinois),
and is prepared as follows. The polyethylene glycol powder
is diluted in acidic solution A, provided in the packaging.
Approximately 1 to 2 ml of the dilution is applied on the
distal half of the patch. The adhesive is inactive under acidic
conditions and can thus be advanced through the sheath to
the LAA. Activation is accomplished by exposing the
adhesive to alkaline solution B after the device has been
positioned and inflated.
Patch delivery. The device complex is advanced through
the long sheath over the guidewire into the LAA. The
balloon is inflated with dilute contrast until it stretches the
LAA (3 to 10 ml of injectable volume corresponds to 14 to
25 mm patch diameter). Subsequently, alkaline solution B is
injected through the central lumen of the catheter. The
balloon/patch position is confirmed by fluoroscopy and
TEE. The supportive balloon catheter is removed 45 min
after surgical adhesive activation according to the following
procedure: the balloon is deflated, and the catheter assembly
is retracted through the introducing sheath with the tip of
Abbreviations
and Acronyms
LAA  left atrial
appendage
TP  Transcatheter Patch
TEE  transesophageal
echocardiogram
lease (min) Result Indication/Comment
45 FO Bleeding ulcer
45 FO Peptic system bleeding
45 FO Hemorrhagic stroke, LA thrombus
45 TS Ischemic stroke, LA thrombus
45 — Patch not attached, angiography
45 FO Bleeding ulcer
45 PO Previous stroke, gastric ulcer
45 FO Stroke on warfarin
45 FO Heart failure, diabetes, warfarin con.
45 FO Previous stroke, warfarin con.
45 FO Hypertension, diabetes, warfarin con.
45 FO Hypertension, diabetes, warfarin con.
45 FO Warfarin con.
45 FO Bleeding disorder
45 FO Previous stroke
45 FO Previous stroke, hypertension
45 — No attachment, angiography
45 — No attachment, angiography, bleeding
45 FO Long sheath thrombus, anticoagulation
45 FO Warfarin con.occlusion; TP  Transcatheter Patch; TS  trivial shunt.Re
C
T
u
w
F
2
o
A
R
T
i
r
p
a
w
a
i
o
o
o
a
u
t
a
w
r
w
r
D
T
a
v
e
2238 Toumanides et al. JACC Vol. 58, No. 21, 2011
Transcatheter Patch LA Appendage Closure November 15, 2011:2236–40the sheath held against the patch; the position and stability
of the patch is confirmed by pulling lightly on the retrieval
thread under echocardiography. If the result is satisfactory,
the patch is released by removing the double nylon thread.
Diagnostic angiography was performed in 3 cases directly
before device implantation as well as during the 45-min
waiting period before patch release. Transesophageal echo-
cardiography was used to evaluate the result after balloon
catheter withdrawal and on follow-up. Images depicting a
LAA before and after occlusion can be seen in Figures 2 and 3.
ephalosporins were given prophylactically intravenously.
he patient was observed overnight in the intensive care
nit, and an aspirin regimen (300 mg daily) was started
ithin 24 h.
Figure 2 LAA Before Occlusion
LA  left atrium; LAA  left atrial appendage.
Figure 1 Transcatheter Patch
The Transcatheter Patch device for occlusion of heart defects is tailored from
polyurethane foam. Diluted contrast inflates the supporting balloon to diame-
ters of 15 to 25 mm. A 2-mm nylon loop is sutured at the bottom of the patch,
and a double nylon thread is connected for retrieval purposes.pollow-up. Follow-up TEE was performed on all patients
4 h after device implantation. Clinical follow-up was
btained by the primary physician for at least 1 year.
dditional TEEs were obtained in selected cases.
esults
he LAA was entered after successful transseptal puncture
n all patients. Measurements of the appendage mouth size
evealed a range from 15 to 24 mm in diameter among
atients. In the 17 procedures that were carried out without
ngiography, TP placement was successful. In the 3 cases in
hich angiography was performed, the patch was not
ttached after 45 min and was retrieved through the
ntroducing sheath. All other patients had their appendages
ccluded. In 1 case, the patch was placed beyond the mouth
f the appendage, resulting in a residual opening. The
cclusion result improved significantly within 24 h as
ssessed by the follow-up TEE. In 1 case, there was some
ncertainty related to the stability of the patch, and vigorous
est pulling was used for confirmation. This case presented
complication directly after device release in that thrombus
as extracted from the tip of the long sheath. The thrombus
equired aggressive treatment and was resolved within 1
eek; the atrial appendage remained fully occluded. No
ecurrent strokes or bleeding complications were reported.
iscussion
he TP has been shown to be effective in the occlusion of
variety of heart defects including atrial septal defect,
entricular septal defect, patent ductus arteriosus, and pat-
nt foramen ovale (10–12). Occlusion of the LAA has the
Figure 3 LAA After TP Occlusion
For more information on this case, please see the Online Video. LA  left
atrium; LAA  left atrial appendage; LV  left ventricle; TP  Transcatheter
Patch.otential of being an ideal application for the TP, given
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The TP is made from porous polyurethane, which normally
attaches to the cardiac tissue by fibrin formation within 48 h
(13). In the present study, the attachment time was short-
ened through the use of a pH-activated surgical adhesive.
Since balloon inflation effectively seals the LAA, solution B
could be injected to cause a localized pH shift distally to the
balloon. That led to a further reduction in the attachment
time beyond that possible using the surgical adhesive tech-
nique in other lesions (14). On the basis of the animal
studies mentioned previously, an attachment time closer to
15 min may be possible, but further work is needed to
confirm its safety. The adhesive has been used extensively
after cardiac or peripheral vascular surgery, where mixing of
the components is performed simultaneously (15). It is
bioabsorbable and is eliminated from the body within 1
month. An additional property of the adhesive is that it
increases in volume after placement owing to water absorp-
tion; this may explain the improvement in appendage
occlusion after 24 h.
In all 3 failed procedures in this study, diagnostic angiog-
raphy had been performed. We speculate that the contrast
medium may have interfered with the adhesion by causing a
change in pH. Consequently, use of angiography may be
contraindicated with this method, but further in vitro
studies are required to confirm this assertion. An additional
drawback of the method is the inconvenience related to the
45-min waiting period, although this is significantly less than
with other lesions. The single complication of acute thrombus
that was observed in this study was likely related to vigorous
operator manipulations. As we have not encountered this
problem previously, we expect that it will not occur if such
manipulations are avoided.
Study limitations. A limitation of this study was that the
appendages used were of relatively small size (25 mm).
Hence, the effectiveness of the method remains unproven in
larger sizes, although we expect an improvement over atrial
septal defect occlusion for which the method is only effective
for defects25 mm (14). The most recent model of the TP,
the Immediate Release Patch, may offer solutions to these
problems as fixation within the appendage is immediate by
expansion; adhesion to tissue takes place several hours later
through fibrin formation (16). Additionally, the drawbacks
related to safe attachment time, long sheath thrombus
formation, and contraindication to angiography should be
eliminated.
Conclusions
In this study, we have shown that LAA occlusion using the
TP in conjunction with surgical adhesives is feasible and
safe in most cases. Neither stroke nor thrombogenicity was
reported on follow-up, but the study was not designed to
prove noninferiority to other treatments. Despite this draw-
back, it is reasonable to assume that the long-term results of
the TP used in stroke prevention should be similar to thosefor the Watchman device and not inferior to warfarin (17).
Furthermore, the fast endothelialization of the wireless
patch prevents the need for anticoagulant treatment, which
is used for a few days after Watchman device implantation.
In conclusion, the TP, used with surgical adhesives, can
offer an alternative to LAA occlusion with metal devices.
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